STRS Ohio’s Cartesian Therapeutics RNAC Stock Holding History

STRS Ohio’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,263	Closed	-$46K	–	2248
2022 Q1	$46K	Hold	1,263	–	–	﹤0.01%	1956
2021 Q4	$123K	Hold	1,263	–	–	﹤0.01%	1855
2021 Q3	$157K	Buy	1,263 +973	+336%	+$117K	﹤0.01%	1839
2021 Q2	$36K	Buy	+290	New	+$34.5K	﹤0.01%	2143
2017 Q4	–	Sell	-53	Closed	-$29K	–	1929
2017 Q3	$29K	Hold	53	–	–	﹤0.01%	1851
2017 Q2	$31K	Hold	53	–	–	﹤0.01%	1853
2017 Q1	$22K	Hold	53	–	–	﹤0.01%	1828
2016 Q4	$27K	Hold	53	–	–	﹤0.01%	1842
2016 Q3	$22K	Buy	+53	New	+$20.7K	﹤0.01%	1834

Other funds holding RNAC

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

STRS Ohio's RNAC Position: Q2 2022 in Review

STRS Ohio sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 1,263 shares — an estimated $46K sold.

STRS Ohio first reported a position in RNAC in Q3 2016 and held it in 9 quarters. The position peaked at $157K in Q3 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

STRS Ohio reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 1,263 Cartesian Therapeutics shares in Q2 2022, an estimated $46K.
STRS Ohio first reported a position in Cartesian Therapeutics in Q3 2016 and held it in 9 quarters.
STRS Ohio's Cartesian Therapeutics position peaked at $157K in Q3 2021.
92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.